Literature DB >> 23035176

Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.

Jun Fujii1, Mariko Naito, Takashi Yutsudo, Sohkichi Matsumoto, Daniel P Heatherly, Takeshi Yamada, Hideyuki Kobayashi, Shin-Ichi Yoshida, Tom Obrig.   

Abstract

We have developed a novel vaccine against Shiga toxin (Stx)-producing Escherichia coli (STEC) infection using a recombinant Mycobacterium bovis BCG (rBCG) system. Two intraperitoneal vaccinations with rBCG expressing the Stx2 B subunit (Stx2B) resulted in an increase of protective serum IgG and mucosal IgA responses to Stx2B in BALB/c mice. When orally challenged with 10(3) CFU of STEC strain B2F1 (O91: H21), the immunized mice survived statistically significantly longer than the nonvaccinated mice. We suggest that intraperitoneal immunization with rBCG expressing Stx2B would be a potential vaccine strategy for STEC.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23035176      PMCID： PMC3535872          DOI： 10.1128/CVI.00473-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  37 in total

1.  Magnetic resonance imaging of brain lesions of a patient with hemolytic uremic syndrome following Escherichia coli O157 infection.

Authors:  A Yasuhara; A Araki; A Ochi; Y Kobayashi
Journal:  Pediatr Int       Date:  2000-06       Impact factor: 1.524

Review 2.  Recombinant BCG vaccines.

Authors:  N Ohara; T Yamada
Journal:  Vaccine       Date:  2001-07-20       Impact factor: 3.641

3.  Elastase in intestinal mucus enhances the cytotoxicity of Shiga toxin type 2d.

Authors:  J F Kokai-Kun; A R Melton-Celsa; A D O'Brien
Journal:  J Biol Chem       Date:  2000-02-04       Impact factor: 5.157

4.  Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms.

Authors:  Alexander W Friedrich; Martina Bielaszewska; Wen-Lan Zhang; Matthias Pulz; Thorsten Kuczius; Andrea Ammon; Helge Karch
Journal:  J Infect Dis       Date:  2001-12-14       Impact factor: 5.226

5.  Cross-protection against challenge by intravenous Escherichia coli verocytotoxin 1 (VT1) in rabbits immunized with VT2 toxoid.

Authors:  K Ludwig; M A Karmali; C R Smith; M Petric
Journal:  Can J Microbiol       Date:  2002-01       Impact factor: 2.419

6.  Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany.

Authors:  Christina Frank; Dirk Werber; Jakob P Cramer; Mona Askar; Mirko Faber; Matthias an der Heiden; Helen Bernard; Angelika Fruth; Rita Prager; Anke Spode; Maria Wadl; Alexander Zoufaly; Sabine Jordan; Markus J Kemper; Per Follin; Luise Müller; Lisa A King; Bettina Rosner; Udo Buchholz; Klaus Stark; Gérard Krause
Journal:  N Engl J Med       Date:  2011-06-22       Impact factor: 91.245

7.  Oral recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity.

Authors:  Mamoru Kawahara; Akira Hashimoto; Ichiro Toida; Mitsuo Honda
Journal:  Clin Immunol       Date:  2002-12       Impact factor: 3.969

8.  Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.

Authors:  M A Karmali; B T Steele; M Petric; C Lim
Journal:  Lancet       Date:  1983-03-19       Impact factor: 79.321

9.  Relative colonizing abilities of human fecal and K 12 strains of Escherichia coli in the large intestines of streptomycin-treated mice.

Authors:  M L Myhal; D C Laux; P S Cohen
Journal:  Eur J Clin Microbiol       Date:  1982-06       Impact factor: 3.267

10.  Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods.

Authors:  Romina J Fernández-Brando; Leticia V Bentancor; María Pilar Mejías; María Victoria Ramos; Andrea Exeni; Claudia Exeni; María del Carmen Laso; Ramón Exeni; Martín A Isturiz; Marina S Palermo
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240
View more
  10 in total

Review 1.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors.

Authors:  Bryan E Hart; Rose Asrican; So-Yon Lim; Jaimie D Sixsmith; Regy Lukose; Sommer J R Souther; Swati D G Rayasam; Joseph W Saelens; Ching-Ju Chen; Sarah A Seay; Linda Berney-Meyer; Leslie Magtanong; Kim Vermeul; Priyadharshini Pajanirassa; Amanda E Jimenez; Tony W Ng; David M Tobin; Steven A Porcelli; Michelle H Larsen; Joern E Schmitz; Barton F Haynes; William R Jacobs; Sunhee Lee; Richard Frothingham
Journal:  Clin Vaccine Immunol       Date:  2015-04-29

3.  Role for Gr-1+ cells in the control of high-dose Mycobacterium bovis recombinant BCG.

Authors:  Michael W Panas; Norman L Letvin
Journal:  Clin Vaccine Immunol       Date:  2014-06-11

Review 4.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 5.  Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

Authors:  Victor A Garcia-Angulo; Anjana Kalita; Alfredo G Torres
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

6.  Comparative genomics and immunoinformatics approach for the identification of vaccine candidates for enterohemorrhagic Escherichia coli O157:H7.

Authors:  Víctor A García-Angulo; Anjana Kalita; Mridul Kalita; Luis Lozano; Alfredo G Torres
Journal:  Infect Immun       Date:  2014-03-04       Impact factor: 3.441

Review 7.  Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Authors:  Yuan-qiang Zheng; Youssef W Naguib; Yixuan Dong; Yan-chun Shi; Shorgan Bou; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2015       Impact factor: 5.217

Review 8.  Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype.

Authors:  Elias A Rahal; Sukayna M Fadlallah; Farah J Nassar; Natalie Kazzi; Ghassan M Matar
Journal:  Front Cell Infect Microbiol       Date:  2015-03-18       Impact factor: 5.293

Review 9.  Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli.

Authors:  Sabrina Mühlen; Petra Dersch
Journal:  Front Cell Infect Microbiol       Date:  2020-05-06       Impact factor: 5.293

Review 10.  Intestinal Pathogenic Escherichia coli: Insights for Vaccine Development.

Authors:  Maricarmen Rojas-Lopez; Ricardo Monterio; Mariagrazia Pizza; Mickaël Desvaux; Roberto Rosini
Journal:  Front Microbiol       Date:  2018-03-20       Impact factor: 5.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.